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Bone massa b s t r a c t
Early B-cell factor 1 (Ebf1) is a transcription factor whose inactivation in all cells results in high bone
mass because of an increase in bone formation. This observation suggests Ebf1 may be an inhibitor
of osteoblast differentiation. To test this contention, we analyzed Ebf1 pattern of expression and
function in osteoblasts ex vivo and in vivo through osteoblast-speciﬁc inactivation in the mouse.
We show here that in vivo deletion of Ebf1 in osteoblast progenitors does not affect osteoblast dif-
ferentiation or bone formation accrual post-natally. These observations indicate that the phenotype
described in Ebf1/ mice is not osteoblast-autonomous.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Our understanding of the transcriptional control of the differen-
tiation processes that generate, during embryonic development,
the various cell types of mesenchymal origin, i.e., the osteoblast,
chondrocyte, myoblast, and adipocyte, has made considerable pro-
gress during the past two decades. Although these cell types derive
from a common progenitor, the mesenchymal stem cell (MSC),
their differentiation along various lineages depends on distinct sets
of transcription factors. In particular, the early steps of differentia-
tion of MSCs to osteoblasts require the function of Runx2,while la-
ter steps of differentiation involve at least two other transcription
factors, Osterix and Atf4 [1].
Besides the cardinal transcription factors mentioned above,
many others have been shown to affect osteoblast differentiation
either by modulating Runx2 activity or by functioning indepen-
dently of Runx2. Twist and Schnurri-3 are two examples of the for-
mer [2,3], while members of the AP-1 family and Creb act
independently of Runx2 to affect osteoblast differentiation and pro-
liferation [4,5]. Another factor for which mouse genetics has given
clear indications that it contributes to osteoblast phenotype is
Ebf1.Early B-cell factor 1 (Ebf1) is a member of a small family of tran-
scription factors that contains an atyptical zinc ﬁnger DNA binding
domain and a non-basic helix-loop-helix (HLH) dimerization do-
main [6]. Originally cloned as a putative B-cell transcription factor,
Ebf1 was conﬁrmed by loss-of-function experiments in the mouse
to be a pioneer factor essential for the commitment and mainte-
nance of B-cell fate [6,7]. The cell differentiation ability of Ebf1
has been expanded to neurons of the embryonic striatum during
mouse development [8]. More recently, two indirect but conver-
gent lines of evidence raised the prospect that Ebf1 may prevent
osteoblast differentiation and instead favor allocation of MSCs to-
ward the adipocyte lineage.
First, in the pre-adipogenic 3T3L1 cell line Ebf1 promotes PPARc
expression, while reducing Ebf1 expression inhibits the adipocyte
differentiation potential of this cell line [9,10]. Second, and more
importantly for our purpose, analysis of mice lacking Ebf1 in all
cells revealed a marked increase in the number of osteoblasts
and in bone formation parameters [11,12]. This experiment estab-
lished Ebf1 as a negative regulator of osteoblast differentiation. As
importantly, that this high bone mass phenotype was observed in
mice lacking Ebf1, but not other members of this small family of
transcription factors, indicated that there was no overt redundancy
between Ebf1 and other members of the Ebf family when it comes
to the regulation of osteoblast differentiation.
In view of the strong phenotype of Ebf1/mice and of Ebf1 dif-
ferentiation ability in other cell lineages, it is legitimate to suspect
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manner. To determine if this is indeed the case we relied on Ebf1
knockdown in cell culture and the analysis of mutant mice lacking
Ebf1 only in cells of the osteoblast lineage. To our surprise, Ebf1
deletion in cells of the osteoblast lineage throughout development
and after birth has no overt deleterious consequences on the differ-
entiation of osteoblasts, bone formation parameters, or overall
bone mass accrual. Taken at face value, these observations identify
Ebf1 as one of the few transcription factors inhibiting osteoblast
differentiation in a non cell-autonomous manner.
2. Materials and methods
2.1. Mice generation
Ebf1ﬂ/+mice were generated as previously described [13]. To
generate osteoblast-speciﬁc Ebf1 deﬁcient mice, Ebfﬂ/ﬂ mice were
crossed with Ebf1ﬂ/+; Runx2–Cre mice, which were then crossed
to Ebfﬂ/ﬂ mice to generate Ebf1osb/ mice. Genotypes of mice were
determined by PCR. Primer sequences are available upon request.
All mice were 1-month old males maintained on the C57BL/6 ge-
netic background.
2.2. In situ hybridization
Embryos were ﬁxed in 4% paraformaldehyde and embedded in
parafﬁn. Radioactive in situ hybridization was performed on 6 lm
sections using 35S-labeled riboprobes. Hybridizations were per-
formed overnight at 55 C, and washes were performed at 63 C.
Autoradiography and Hoechst 33528 staining were performed as
described [14]. Probe sequences available upon request.
2.3. Immunohistochemistry
Embryos were ﬁxed in 4% paraformaldehyde, embedded in
parafﬁn, and sectioned at 7 lm. Immunohistochemistry was
performed using an immunoperoxidase system (ABC Elite Kit,
Vector Laboratories) with anti-Neun (Millipore) or a monoclonal
rat anti-Ebf1 antibody that was previously characterized [13].
Nova Red was used to localize peroxidase.
2.4. Molecular studies
RNA isolation and quantitative PCR were performed following
standard protocols.
2.5. Statistical analysis
Results are given as means ± standard error of means unless
otherwise indicated. Statistical analyses were performed using
the Student’s t-test.
2.6. Cell culture
Primary osteoblasts were cultured and differentiated as previ-
ously described [15]. Cells were transfected with siRNA pools
(on-TARGETplusSMARTpool, Dharmacon) according to manufac-
turer instructions. Ebf1+/+ or Ebf1/ osteoblasts were generated
by infecting Ebf1ﬂ/ﬂ osteoblasts with either green ﬂuorescent pro-
tein (GFP)- or Cre-expressing adenovirus (University of Iowa).
2.7. Chromatin immunoprecipitation (ChIP)
10T1/2 cells were harvested and resuspended in medium at a
concentration of 1 to 2  106 cells/ml. Crosslinking mix (11%formaldehyde, 100 mM NaCl, 0.5 mM EGTA, 1 mM EDTA, 50 mM
Hepes, pH 8.0) was added to a ﬁnal concentration of 1% formalde-
hyde. Crosslinking reaction was stopped after 10 min at room tem-
perature by the addition of glycine to a ﬁnal concentration of
125 mM. Cells were spun down immediately and washed three
times with ice cold PBS. They were resupended in lysis buffer
(1.25% SDS, 12.5 mM EDTA, 62.5 mM Tris–HCl, pH 8.0, protease
inhibitor mix) with a concentration of 20 to 40  106 cells/ml. With
a Bioruptor Standard the chromatin was sheared into pieces of
300–500 bp. This chromatin was stored at 80 C and subse-
quently used for ChIP experiments.
The Ebf1 antibody used is a polyclonal rabbit anti Ebf1 antibody
that detects the N-terminus of b-Ebf1 that was previously charac-
terized [13]. 4 lg of an anti-murine Ebf1 antibody or normal rabbit
IgG (Millipore 12–370) was added for each ChIP. 100 ll chromatin
were diluted 1:10 in dilution buffer (50 mM Tris–HCl, pH 8.0,
5 mM EDTA, 200 mM NaCl, 0.5% NP-40, protease inhibitor mix).
Samples were rotated for 16–20 h at 4 C and washed. Protein-A
Sepharose beads were added for another two hours. Subsequently
beads were washed ﬁve times with wash buffer (0.1% SDS, 1% NP-
40, 2 mM EDTA, 500 mM NaCl, 20 mM Tris–HCl, pH 8.0) and four
times with TE buffer (10 mM Tris–HCl pH8, 1 mM EDTA pH 8.0).
Immunoprecipitated chromatin was eluted two times with 50 ll
elution buffer (2%SDS, 10 mM Tris–HCl pH 8, 1 mM EDTA pH8.0)
for 10 min at 65 C shaking. Elutions were pooled and decross-
linked for at least 6 h at 65 C. DNA was ﬁnally puriﬁed with QIA-
quick PCR Puriﬁcation Kit (Qiagen Cat. No.28106). The puriﬁed
DNA was used in quantitative PCR to analyze binding of Ebf1 to
DNA. Negative controls include chr. II, Pax5, cd79a, CD40, Igll1. Po-
sitive control is Pcgf1.
2.8. Histology
Static and dynamic histomorphetric analyses were performed
on vertebral column specimens collected from 1-month old mice
using undecalciﬁed sections according to standard protocols, and
using the Osteomeasure analysis system (Osteometrics).
3. Results
3.1. Ebf1 is expressed at low levels in osteoblasts during embryonic
development
At the onset of this study and to guide our investigation, we
sought to determine which members of the Ebf family were the
most highly expressed in primary osteoblasts. qPCR analysis using
exonic primers normalized to genomic DNA revealed that in oste-
oblasts, Ebf1was clearly more abundantly expressed than the other
three members of the Ebf family. In cells that were fully differenti-
ated, this difference in level of expression was at least one order of
magnitude (Fig. 1A). Given this result and the important fact that
deletion of Ebf1 in all cells sufﬁces to affect bone mass accrual,
we thus focused the remainder of our analysis on the function
Ebf1 may have in osteoblasts.
We then studied the Ebf1 pattern of expression in the develop-
ing skeleton by in situ hybridization. As previously shown, the mar-
ker of bone formation, Runx2, is robustly expressed in
osteoprogenitors of the developing ribs already at E12.5 [16]. In
contrast, in an adjacent section, the expression of Ebf1 in osteopro-
genitors, although detectable, was signiﬁcantly weaker (Fig. 1B).
Similarly, at E14.5 and E16.5, expression of Runx2 in cells of the
osteoblast lineage was quite high, but expression of Ebf1 remained
barely above the limit of detection (Fig. 1B). Finally, we compared
the expression of Ebf1 in adult tissue, and also observed rather low
expression in bone and cartilage (Fig. 1C). In summary, these
Fig. 1. Ebf1 expression analysis. (A) Normalized expression of Ebf1, 2, 3, and 4 by qPCR in primary osteoblasts differentiated in culture. (B) Expression pattern analysis of Ebf1
in mouse embryos by radioactive in situ hybridization of adjacent sections featuring osteoblast (Runx2) regions. (C) qPCR analysis of Ebf1 expression in adult mouse tissue.
Reference gene is Gapdh. White adipose tissue, WAT. Brown adipose tissue, BAT. (D) Expression pattern analysis of Ebf1 in mouse embryos by immunohistochemistry of
adjacent sections featuring dorsal root ganglion marked by a pan-neuronal marker NeuN.
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Runx2 and is less pronounced than the one of Runx2 during skele-
togenesis, suggesting that Ebf1 may not have a critical role in the
osteoblast even though Ebf1/ mice have high bone mass [11].
Of note, we also investigated the expression pattern of Ebf1 in
other cell types through immunohistochemistry performed in the
embryo at different stages of development. This analysis revealed
high levels of Ebf1 in the dorsal root ganglia and spinal cord,
marked in an adjacent section by a pan-neuronal antibody NeuN
(Fig. 1D).
3.2. Ebf1 affects osteoblast gene expression ex vivo
Next, to determine whether or not Ebf1 may be a cell-autono-
mous molecular suppressor of osteoblast differentiation, we ana-
lyzed the effects of siRNA-mediated down-regulation of Ebf1
mouse osteoblasts that were transfected with a siRNA to tran-
siently suppress Ebf1 expression but not affect Ebf2, 3, or 4 expres-
sion (Fig. 2A).
For that purpose, primary osteoblasts from calvaria of new-
born mice were transfected with Ebf1 siRNA, resulting in a 76%
decrease in Ebf1 expression. We also conﬁrmed that the siRNA
we used was speciﬁcally targeting Ebf1, and did not result in al-
tered expression of Ebf2, 3, or 4 (Fig. 2A). Ebf1 knockdown in pri-
mary osteoblasts increased expression of Osterix, Col1a1,
Osteocalcin, and Alkaline phosphatase (Alpl). These results were
certainly consistent with the notion that Ebf1 acts as a cell-
autonomous inhibitor of osteoblast differentiation. Of note, with-
in the conditions of this experiment, we did not observe any
change in the expression of adipocyte-speciﬁc transcription fac-
tors such as PPARc, C/EBPa, C/EBPb (Fig. 2A).
In view of these results we asked whether Ebf1 directly binds
to some of the genes whose expression was perturbed by its
knockdown in the above-mentioned experiment. With the helpof a genome-wide data set of an Ebf1 ChIPseq experiment, per-
formed in the murine bone marrow stroma cell line OP-9 (Boller
et al. unpublished data), we could identify potential Ebf1 binding
sites. We further validated these sites by quantitative ChIP using
the multipotent mesenchymal cell line 10T1/2, which expresses
Ebf1 (Supplementary Fig. 1). This analysis indicated that Ebf1
binds at multiple sites in the Alpl and Osterix regulatory regions
(Fig. 2B).
3.3. Ebf1-independent osteoblast differentiation in vivo
In view of this encouraging set of ex vivo observations, we
next studied the function of Ebf1 speciﬁcally in osteoblasts
in vivo and crossed Ebf1ﬂ/ﬂ mice with mice expressing Cre recom-
binase under the control of the Runx2 regulatory elements [17].
We chose Runx2-Cre mice to address this question, as Runx2 is
the earliest and also the most speciﬁc molecular marker of the
osteoblast lineage identiﬁed to date [16]. Hence, this Cre driver
would allow us to study Ebf1 function in cells of the osteoblast
lineage at each stage of differentiation. Prior to analyzing these
mice, we veriﬁed that we had achieved efﬁcient deletion of
Ebf1 in osteoblasts. Ebf1 was decreased by 80% in whole bone,
and by more than 95% in osteoblasts derived from bone marrow.
Although Ebf1 expression was also reduced in cartilage, its
expression was not affected in the other tissues tested (Supple-
mentary Fig. 2).
Ebf1osb
/ mice were born at the expected Mendelian ratio, had
normal life expectancy, and appeared overall normal, indicating
that its expression in Runx2-expressing cells is dispensable for
normal embryonic development. Body weight, epididymal fat
pad weight, body and femoral lengths were similar between
Ebf1osb
/ mice and control littermates (Ebf1ﬂ/+, Ebf1ﬂ/ﬂ,and
Runx2-Cremice) (Fig. 3A). To our surprise, bone histomorphometric
analysis performed in vertebrae of 1-month old Ebf1osb/ and
Fig. 2. (A) Ebf1 siRNA knockdown in primary osteoblasts. n.e. not expressed. (B) Analysis of Ebf1 direct targets in a mesenchymal cell line 10T1/2. Binding is represented as a
percentage of input chromatin, and error bars represent standard deviation of duplicate ChIP experiments. Positive control is Pcgf1 and negative control is chr.II.
Fig. 3. Phenotype analysis of Ebf1osb/. (A) Body weight, percent gonadal fat (FPW/BW), body length, and femur length, (B) bone histomorphetric analysis, (C) osteocalcin
measurement in serum (D) qPCR analysis of isolated bone in Ebf1osb/ mice.
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Fig. 4. Ebf1 function in osteoblasts (A) Ebf1-/- osteoblasts stained by von Kossa, and (B) Ebf1/ osteoblasts stained for alkaline phosphatase activity. (C) Ebf1/ osteoblast
gene expression analysis. (D) Overexpression of Ebf1 in MC-3T3E1 cells by western blot and qPCR analysis. (E) MC-3T3E1 cells overexpressing Ebf1 stained for alkaline
phosphatase activity.
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formation rate, and bone mass (Fig. 3B). Serum osteocalcin levels
were similarly unaffected in Ebf1osb/mice (Fig. 3C). Gene expres-
sion analysis performed in bone tissue did not record any of the
changes in gene expression that had been observed in cell culture
experiments (Fig. 3D). This set of observations indicates that
in vivo, Ebf1 does not negatively regulate osteoblast differentiation
through its expression in cells of the osteoblast lineage.
To perform a complete analysis of Ebf1 function in osteoblasts,
we cultured Ebf1/ osteoblasts. Ex vivo, Ebf1/ osteoblasts form
less mineralization nodules and produce slightly less alkaline
phosphatase (Fig. 4A and B), though they display no signiﬁcant
change in Alpl or Osterix expression (Fig. 4C). This result contrasts
with the fact that in vivo, Ebf1osb/ bones have no mineralization
defect (Fig. 3B). In an effort to further explore the signiﬁcance of
this ex vivo observation, we also stably overexpressed Ebf1
(approximately 40% increase) in MC3T3-E1 cells that can mineral-
ize in culture [18] (Fig. 4D). Through this Ebf1 overexpression, we
observed an increase in extracellular matrix mineralization
(Fig. 4E).
4. Discussion
Previous observations stemming from cell culture experiments
and from the analysis of mice lacking Ebf1 in all cells had indicated
that Ebf1 is a negative regulator of osteoblast differentiation and
bone formation [9–11]. These data immediately raised thequestion of whether Ebf1 acts in a cell-autonomous manner to
fulﬁll this function. This is an even more important question given
the fact that among all members of this small family of transcrip-
tion factors, Ebf1 is the most highly expressed in cells of the
osteoblast lineage by far.
Transient Ebf1 loss of function experiments performed in pri-
mary osteoblasts fully supported the notion that Ebf1 negatively
regulates osteoblast-speciﬁc gene expression. Since expression
of important genes for the osteoblast phenotype such as Osterix,
Col1a1, Osteocalcin, and Alpl were increased in cells lacking Ebf1,
these results were fully consistent with the high bone mass
observed in Ebf1/ and suggested that Ebf1 acts in a cell-
autonomous manner to regulate osteoblast differentiation.
Hence, it cameas a surprise that cell-speciﬁc Ebf1deletion in cells
of the osteoblast lineage in the mouse does not have any overt con-
sequences on osteoblast differentiation in vivo. Results of this analy-
sis in Ebf1osb/mouse model are surprising for several reasons.
The ﬁrst reason is that the in vivo results have no clear relation-
ship to what was previously observed in cell culture by others and
by us, after a decrease of Ebf1 expression in differentiated osteo-
blasts [9,10]. As such, these results illustrate how cautious one
should be when making inference about the differentiation ability
of a given transcription factor or of any other regulatory gene
based on cell culture assays alone. This result was even less ex-
pected given the fact that Ebf1 binding sites are present in such
an important regulator of osteoblast differentiation as Osterix. Last,
but not least, these results were also unanticipated because they
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lacking Ebf1, which display high bone mass with a concomitant de-
crease in adiposity [11].
Although the formal possibility remains that Ebf1 function is
masked by the remaining expression of Ebf2, 3, and 4, we note
that mice lacking Ebf1 in all cells present cell differentiation de-
fects even though other Ebfs are normally expressed. Thus we
believe this is an unlikely possibility [19]. At the present time
the most likely interpretation of the unanticipated results
presented here is that the phenotype observed previously in
Ebf1/ mice may be due to a cell-nonautonomous defect. These
results indicate that Ebf1 belongs to a class of transcriptional
regulators of osteoblast differentiation that act in a non cell-
autonomous manner. Possible areas where Ebf1 may function
to regulate bone mass include the dorsal root ganglia and spinal
cord where Ebf1 is highly expressed.
Overall this study underscores how informative a cell-speciﬁc
deletion approach is to study gene function. Indeed, the lack of a
bone phenotype in Ebf1osb/ mice contrasts sharply with the
bone phenotype of Ebf1/ mice, but is in agreement with the
weak expression of Ebf1 in osteoblasts. Our experiments also
indicate that even for processes such as extracellular matrix
mineralization, results can differ between ex vivo and in vivo ap-
proaches. Hence, they suggest that an ex vivo approach only is
not enough to study the role of a given gene in extracellular ma-
trix mineralization. The reasons for this discrepancy will need to
be further addressed.
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